C.R. Bard Stock To Go Ex-dividend Tomorrow (BCR)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for C.R. Bard (NYSE: BCR) is tomorrow, January 17, 2013. Owners of shares as of market close today will be eligible for a dividend of 20 cents per share. At a price of $101.90 as of 9:30 a.m. ET, the dividend yield is 0.8%.

The average volume for C.R. Bard has been 537,600 shares per day over the past 30 days. C.R. Bard has a market cap of $8.45 billion and is part of the health care sector and health services industry. Shares are up 5.1% year to date as of the close of trading on Tuesday.

C. R. Bard, Inc. and its subsidiaries design, manufacture, package, distribute, and sell medical, surgical, diagnostic, and patient care devices worldwide. The company has a P/E ratio of 17.3, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full C.R. Bard Ratings Report.

See our dividend calendar or top-yielding stocks list.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

EY's Greene Sees More Med Tech, CRO Deals Ahead

Deals of the Week: Waiting for Clarity

Merger Buzz Drives Akorn to Top of Health Chart in April

Deals of the Week: Reason for Optimism

Good Medicine Makes for 3 Good Charts